This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About ISENTRESS® 600 mg (raltegravir)

Updated on 15/03/2018

HIV
Welcome to the home page for ISENTRESS (raltegravir) 1200 mg (2 x 600 mg)
Proven efficacy in treatment-naïve adults and demonstrated tolerability1
Can be used with a range of medications1,a
Convenience of once-daily dosing1-3

ISENTRESS 600 mg is indicated for use in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in patients weighing at least 40 kg.

Now you can prescribe ISENTRESS 600 mg for
once-daily dosing at 1200 mg (2 x 600 mg)

Proven Efficacy1,2
  • Effective viral suppression regardless of baseline viral load, comparable with ISENTRESS 400 mg1,2
  • Similar increases in CD4
    count compared with ISENTRESS 400 mg1,2
Demonstrated Tolerability2
  • No drug-related moderate to severe clinical adverse events occurred at a rate of ≥2% in either treatment groups across 48 weeks
Now once daily
  • Flexibility and simplicity with once-daily dosing1-3

Which of your patients would be suitable for ISENTRESS 600 mg1

Evolving needs, whole person care – life course of HIV

References

  1. ISENTRESS 600 mg Summary of Product Characteristics.
  2. Cahn et al. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV 2017;N/A: 1-9.
  3. ISENTRESS Summary of Product Characteristics.
  4. Samuel L Brilleman et al . Implications of comorbidity for primary care costs in the UK. British Journal of General Practice. 2013;N/A: 1-9.
  5. Rockstroh. Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK. J Acquir Immune Defic Syndr. 2013;63 (1) May 1: 77-85 (+ appendix).

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

INFC-1246450-0000 | Date of Preparation: March 2018